Get the Stockscreener App
5.07
2.50%
-0.13
After Hours:
4.99
-0.08
-1.58%
Nls Pharmaceutics Ltd stock is traded at $5.07, with a volume of 64,247.
It is down -2.50% in the last 24 hours and down -14.99% over the past month.
NLS Pharmaceutics Ltd is a biopharmaceutical company. It is engaged in the discovery and development of life-improving drug therapies to treat rare and complex CNS disorders. It focuses on developing therapeutics for the treatment of neurobehavioral and neurocognitive disorders. The company's tangible assets are held in the United States. Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.
See More
Previous Close:
$5.20
Open:
$5.15
24h Volume:
64,247
Relative Volume:
0.46
Market Cap:
$222.30M
Revenue:
-
Net Income/Loss:
$-15.47M
P/E Ratio:
-6.0357
EPS:
-0.84
Net Cash Flow:
$-13.51M
1W Performance:
-6.53%
1M Performance:
-14.99%
6M Performance:
-29.58%
1Y Performance:
-81.89%
1-Day Range:
$4.7422
$5.20
1-Week Range:
$4.08
$5.95
52-Week Range:
$4.08
$40.60
Nls Pharmaceutics Ltd Stock (NLSP) Company Profile
Nls Pharmaceutics Ltd Stock (NLSP) Latest News
NLSP stock touches 52-week high of $4.61 amid market fluctuations - Investing.com
NLSP stock touches 52-week high of $4.61 amid market fluctuations - Investing.com UK
NLS Pharmaceutics announces 1-for-40 reverse stock split - Investing.com
NLS Pharmaceutics Ltd. Announces Expected Implementation of 1-for-40 Reverse Share Split - AccessWire
NLS Pharmaceutics Ltd. Announces Expected Implementation of 1-for-40 Reverse Share Split - StockTitan
A year in review: NLS Pharmaceutics Ltd (NLSP)’s performance in the last year - US Post News
Market Highlights: NLS Pharmaceutics Ltd (NLSP) Ends on a Low Note at 0.14 - The Dwinnex
NLSP: Riding the Market Waves of Growth and Decline in 2023 - The InvestChronicle
NLS Pharmaceutics Shareholders Approve Key Measures - TipRanks
NLS Pharmaceutics Adjusts Warrants Terms - TipRanks
NLS Pharmaceutics Plans Capital Increase and Debt Restructuring - TipRanks
Investor’s Toolkit: Key Ratios for Assessing NLS Pharmaceutics Ltd (NLSP)’s Performance - The Dwinnex
What was NLS Pharmaceutics Ltd (NLSP)’s performance in the last session? - US Post News
NLSP’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - The InvestChronicle
Market Update: NLS Pharmaceutics Ltd (NLSP) Sees Negative Movement, Closing at 0.16 - The Dwinnex
NLS Pharmaceutics Prepares for Share Consolidation - TipRanks
A stock that deserves closer examination: NLS Pharmaceutics Ltd (NLSP) - US Post News
NLS Pharmaceutics (NASDAQ:NLSP) Trading 4.3% Higher - Defense World
NLS Pharmaceutics Gains PwC’s Endorsement - TipRanks
NLS Pharmaceutics to Merge with Cell Therapy Developer Kadimastem - Sleep Review
NLS Pharmaceutics Announces CFO Departure Amidst Merger Plans - TipRanks
It is Poised to be a Bull Market for NLS Pharmaceutics Ltd (NLSP) - SETE News
NLS Pharmaceutics Ltd (NLSP) stock analysis: A simple moving average approach - US Post News
Views of Wall Street’s Leading Experts on NLS Pharmaceutics Ltd - SETE News
Quarterly Snapshot: Quick and Current Ratios for NLS Pharmaceutics Ltd (NLSP) - The Dwinnex
Daily Market Movement: NLS Pharmaceutics Ltd (NLSP) Sees a -9.34 Decrease, Closing at 0.22 - The Dwinnex
NLS Pharmaceutics Ltd [NLSP] Stock trading around $0.23 per share: What’s Next? - The DBT News
NLS Pharmaceutics to merge with Kadimastem in stock deal By Investing.com - Investing.com Nigeria
NLS Pharmaceutics to merge with Kadimastem in stock deal - Investing.com India
NLSP’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle
NLSP Stock: NLS Pharmaceutics A Beacon of Hope in CNS Disorder Treatment - All Finance Times
NLS Pharmaceutics to merge with Kadimastem in stock deal - Investing.com
NLS Pharmaceutics to Absorb Kadimastem as Subsidiary After Agreeing to Merger - MarketWatch
NLS Pharmaceutics and Kadimastem Announce Binding Term Sheet to Merge - AccessWire
NLS Pharmaceutics and Kadimastem Announce Binding Term Sheet to Merge - StockTitan
Kadimastem Ltd signed a letter of intent to acquire NLS Pharmaceutics AG in a reverse merger transaction. - Marketscreener.com
NLS Pharmaceutics Ltd (NLSP) Stock: A Year of Highs and Lows - The InvestChronicle
Market Insights: NLS Pharmaceutics Ltd (NLSP)’s Notable Gain of 4.76, Closing at 0.22 - The Dwinnex
NLS Pharmaceutics Ltd: Weathering Stock Market Storms with 10.25M Market Cap - The InvestChronicle
NLS Pharmaceutics Ltd (NLSP)’s highs and lows: A closer look at its stock price fluctuations - US Post News
Short Interest in NLS Pharmaceutics Ltd. (NASDAQ:NLSP) Rises By 2,335.2% - Defense World
NLS Pharmaceutics Ltd (NLSP) Stock: The Story of a 52-Week Stock Range - The InvestChronicle
NLS Pharmaceutics Ltd (NLSP)’s Day in Review: Closing at 0.19, Down by -6.34 - The Dwinnex
NLS Pharmaceutics (NASDAQ:NLSP) Shares Down 6.3% - Defense World
Deeper Dive: Understanding NLS Pharmaceutics Ltd (NLSP) Through its Various Ratios - The Dwinnex
NLS Pharmaceutics Ltd (NLSP) Stock: Exploring a Year of Highs, Lows, and Trading Volume - The InvestChronicle
Was anything negative for NLS Pharmaceutics Ltd (NLSP) stock last session? – US Post News - US Post News
NLS Pharmaceutics Unveils New Share Purchase Warrant - TipRanks
Form 424B5 NLS Pharmaceutics Ltd. - StreetInsider.com
NLS Pharmaceutics Ltd [NLSP] moved up 31.43: Why It’s Important - The DBT News
Tamboran Resources director buys $158,400 in company stock By Investing.com - Investing.com
Nls Pharmaceutics Ltd Stock (NLSP) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):